Eli Lilly and Company (LLY) Forms Strategic Collaboration with Repertoire Immune Medicines

Eli Lilly and Company (NYSE:LLY) is included among the 7 Best Low-Risk Dividend Stocks to Invest in.

Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.

According to a January 29 report by Reuters, Eli Lilly and Company (NYSE:LLY) is teaming up with Repertoire Immune Medicines in a partnership that could be worth as much as $1.93 billion. The focus is on developing new treatments for multiple autoimmune diseases.

Under the deal, Repertoire will receive $85 million upfront, with the potential for another $1.84 billion tied to development and commercial milestones. The agreement also includes tiered royalties on future net sales. The goal is to create therapies that restore the immune system and deliver lasting disease remission, without relying on the broad immune suppression seen in many current treatments.

As part of the collaboration, Lilly will gain access to Repertoire’s Decode platform, which studies how T cells recognize and bind to specific targets on diseased cells. Repertoire will run the work through early discovery, after which Lilly will take over clinical development, manufacturing, regulatory activities, and commercialization.

Repertoire CEO Torben Nissen said the company is also advancing programs aimed at identifying and developing treatments for several solid tumors, including lung, breast, and head and neck cancers.

Lilly has been steadily building out its immunology business through deals and acquisitions. That push includes the $3.2 billion purchase of Morphic Holding in 2024, a move designed to strengthen its inflammatory bowel disease pipeline.

Today, Eli Lilly and Company (NYSE:LLY)’s immunology portfolio includes medicines such as Olumiant, Taltz, and Omvoh. These treatments are used across conditions ranging from arthritis and immune-related hair loss to inflammatory skin diseases like psoriasis and chronic bowel disorders such as ulcerative colitis.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High Yield Utility Stocks to Buy in 2026 and 10 Best American Oil and Gas Stocks to Buy.

Disclosure: None.